LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.32 1.54

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.29

Max

1.35

Põhinäitajad
By Trading Economics
Sissetulek	2.7M -24M
Aktsiakasum	-0.354
Töötajad	171
EBITDA	-5.3M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+103.82% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-615K 80M
Eelmine avamishind	-0.22
Eelmine sulgemishind	1.32

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. märts 2026, 22:42 UTC

Tulu

Prudential PLC 2025 Adjusted Operating Profit Rises

17. märts 2026, 21:40 UTC

Tulu

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17. märts 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17. märts 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17. märts 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. märts 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17. märts 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17. märts 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17. märts 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17. märts 2026, 22:07 UTC

Tulu

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17. märts 2026, 22:05 UTC

Tulu

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17. märts 2026, 22:04 UTC

Tulu

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17. märts 2026, 22:03 UTC

Tulu

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17. märts 2026, 21:26 UTC

Tulu

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17. märts 2026, 21:09 UTC

Tulu

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:07 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:06 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Net $757.2M >ATD.T

17. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

103.82% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 103.82%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.